Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 14, 2015; 21(14): 4358-4364
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4358
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4358
Table 2 Trial and patient characteristics
| Study | Disease stage | Follow-up months | Trial randomization | Lost to follow-up | Survival analysis |
| Kim et al[23] | Advanced gastric cancer, chemotherapy-naive | 0.5-39.2 | Yes | Recorded | ITT |
| Lee et al[22] | Elderly patients (aged ≥ 65 yr) Advanced gastric cancer | Capecitabine: 21.9; S-1: 21.7 | Yes | Recorded | ITT |
| Zhang et al[21] | Gastric cancer after surgery | 24 | Yes | Recorded | Evaluable |
| Xiong et al[20] | Advanced gastric cancer, chemotherapy-naive | 2-28 | Yes | Recorded | ITT |
-
Citation: He AB, Peng XL, Song J, Zhang JX, Dong WG, Luo RF, Tang Y. Efficacy of S-1
vs capecitabine for the treatment of gastric cancer: A meta-analysis. World J Gastroenterol 2015; 21(14): 4358-4364 - URL: https://www.wjgnet.com/1007-9327/full/v21/i14/4358.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i14.4358